<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035069</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-IIT-02</org_study_id>
    <nct_id>NCT05035069</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ciprofol Compared to Propofol for Nonintubated General Anesthesia in Patients Undergoing TAVR</brief_title>
  <official_title>A Randomized, Single-Blinded, Parallel Single-Center Clinical Study Exploring the Efficacy and Safety of Ciprofol and Propofol for Nonintubated General Anesthesia in Patient Undergoing Transcatheter Aortic Valve Replacement (TAVR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy and safety of ciprofol compared to&#xD;
      propofol for non-intubated general anesthesia in patients undergoing transcatheter aortic&#xD;
      valve replacement (TAVR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study in subjects undergoing transcatheter aortic valve replacement (TAVR). As&#xD;
      designed, the study will include 1-day screening period, 1-day observation period, and 1-day&#xD;
      safety follow-up. Participants will be randomly assigned to either experimental or control&#xD;
      group with a 1:1 allocation, with 12 subjects in each group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 3, 2021</start_date>
  <completion_date type="Anticipated">February 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 3, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of time that BIS value is maintained between 40 and 60 (including boundary value)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from the start of drug infusion to the first BIS reduction to 60</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from the end of drug infusion to the recovery of BIS to 90</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects received rescue treatment</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypotension</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Anesthesia, General</condition>
  <arm_group>
    <arm_group_label>Ciprofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofol</intervention_name>
    <description>Ciprofol infusion, starting with 0.8 ~ 1mg/kg/h until BIS value below 60 (including 60), and then 0.2 ~ 0.6mg/kg/h until the end of the operation, ciprofol infusion was adjusted to keep the BIS value between 40-60.</description>
    <arm_group_label>Ciprofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol infusion, starting with 4 ~ 5mg/kg/h until BIS value below 60 (including 60), and then 1 ~ 3mg/kg/h until the end of the operation, propofol infusion was adjusted to keep the BIS value between 40-60.</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient scheduled for TAVR through femoral artery access&#xD;
&#xD;
          -  1h ≤ Expected duration of surgery ≤ 3h&#xD;
&#xD;
          -  Planned for general anesthesia without intubation&#xD;
&#xD;
          -  18 ≤ BMI ≤ 30&#xD;
&#xD;
          -  ASA category Ⅱ～Ⅳ&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to anesthesia/sedation or a history of adverse reaction to&#xD;
             anesthesia/sedation&#xD;
&#xD;
          -  Known allergies to eggs, soy products, opioids and their antidotes, propofol, etc;&#xD;
             Contraindications of propofol, opioids and their antidotes&#xD;
&#xD;
          -  Shock and hypotension difficult that is to be corrected by vasoactive drugs in the&#xD;
             screening period&#xD;
&#xD;
          -  Hemoglobin (HB) &lt; 10.0 g / dl (100 g / L)&#xD;
&#xD;
          -  Judged by the investigator to have any other factors that make the subject unsuitable&#xD;
             for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Yan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital of Zhejiang University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fangqiong Li</last_name>
    <phone>+86 02867258840</phone>
    <email>lifangq@haisco.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Min Yan, M.D.</last_name>
      <email>zryanmin@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

